Longeveron (LGVN) 10-Q 12 May 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 10, 2023
Document Information Line Items
Entity Registrant Name	Longeveron Inc.
Trading Symbol	LGVN
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001721484
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-40060
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-2174146
Entity Address, Address Line One	1951 NW 7th Avenue
Entity Address, Address Line Two	Suite 520
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33136
City Area Code	(305)
Local Phone Number	909-0840
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Class A Common Stock
Document Information Line Items
Entity Common Stock, Shares Outstanding		6,226,225
Class B Common Stock
Document Information Line Items
Entity Common Stock, Shares Outstanding		14,855,539

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,984	$ 10,503
Marketable securities	8,693	9,155
Prepaid expenses and other current assets	1,097	404
Accounts and grants receivable	96	218
Total current assets	14,870	20,280
Property and equipment, net	2,810	2,949
Intangible assets, net	2,425	2,409
Right-of-use (ROU) asset	1,456	1,531
Other assets	247	244
Total assets	21,808	27,413
Current liabilities:
Accounts payable	457	1,751
Accrued expenses	613	650
Current portion of lease liability	571	564
Estimated lawsuit liability	1,398	1,398
Deferred revenue	556	506
Total current liabilities	3,595	4,869
Lease liability	1,895	2,041
Total long-term liabilities	1,895	2,041
Total liabilities	5,490	6,910
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.001 par value per share, 5,000,000 shares authorized, no shares issued and outstanding at March 31, 2023, and December 31, 2022.
Class A Common Stock, $0.001 par value per share, 84,295,000 shares authorized, 6,163,050 shares issued and outstanding at March 31, 2023: 6,127,320 issued and outstanding, at December 31, 2022	6	6
Class B Common Stock, $0.001 par value per share, 15,705,000 shares authorized, 14,871,085 shares issued and outstanding at March 31, 2023: 14,891,085 issued and outstanding, at December 31, 2022	15	15
Additional paid-in capital	84,116	83,712
Stock subscription receivable	(100)	(100)
Accumulated deficit	(67,420)	(62,773)
Accumulated other comprehensive loss	(299)	(357)
Total stockholders’ equity	16,318	20,503
Total liabilities and stockholders’ equity	$ 21,808	$ 27,413

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Class A Common Stock
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	84,295,000	84,295,000
Common stock, shares issued	6,163,050	6,127,320
Common stock, shares outstanding	6,163,050	6,127,320
Class B Common Stock
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	15,705,000	15,705,000
Common stock, shares issued	14,871,085	14,891,085
Common stock, shares outstanding	14,871,085	14,891,085

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues
Clinical trial revenue	$ 238	$ 310
Grant revenue	41	60
Total revenues	279	370
Cost of revenues	203	205
Gross profit	76	165
Operating expenses
General and administrative	1,855	1,980
Research and development	2,780	1,292
Selling and marketing	157	287
Total operating expenses	4,792	3,559
Loss from operations	(4,716)	(3,394)
Other income and (expenses)
Other income (expenses), net	69	(116)
Total other income and (expenses), net	69	(116)
Net loss	$ (4,647)	$ (3,510)
Basic and diluted net loss per share (in Dollars per share)	$ (0.22)	$ (0.17)
Basic and diluted weighted average common shares outstanding (in Shares)	21,033,610	20,911,203

Condensed Statements of Opera_2

Condensed Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Diluted net loss per share	$ (0.22)	$ (0.17)
Diluted weighted average common shares outstanding	21,033,610	20,911,203

Condensed Statements of Compreh

Condensed Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (4,647)	$ (3,510)
Other comprehensive loss:
Net unrealized gains on available-for-sale securities	58
Total comprehensive loss	$ (4,589)	$ (3,510)

Condensed Statements of Stockho

Condensed Statements of Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Class A Common Stock	Class B Common Stock	Subscription Receivable	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balance at Dec. 31, 2021	$ 5	$ 16	$ (100)	$ 81,470	$ (43,938)		$ 37,453
Balance (in Shares) at Dec. 31, 2021	5,175,361	15,702,834
Conversion of Units into Class A and B common stock
Conversion of Units into Class A and B common stock (in Shares)	117,772	(117,772)
Class A Common Stock, issued for RSUs vested
Class A Common Stock, issued for RSUs vested (in Shares)	44,006
Class A Common Stock, held for taxes on RSUs vested				(128)			(128)
Class A Common Stock, held for taxes on RSUs vested (in Shares)	(10,626)
Equity-based compensation				491			491
Net loss					(3,510)		(3,510)
Balance at Mar. 31, 2022	$ 5	$ 16	(100)	81,833	(47,448)		34,306
Balance (in Shares) at Mar. 31, 2022	5,326,512	15,585,062
Balance at Dec. 31, 2022	$ 6	$ 15	(100)	83,712	(62,773)	(357)	20,503
Balance (in Shares) at Dec. 31, 2022	6,127,320	14,891,085
Conversion of Class B common stock for Class A common stock
Conversion of Class B common stock for Class A common stock (in Shares)	20,000	(20,000)
Class A Common Stock, issued for RSUs vested
Class A Common Stock, issued for RSUs vested (in Shares)	20,161
Class A Common Stock, held for taxes on RSUs vested				(17)			(17)
Class A Common Stock, held for taxes on RSUs vested (in Shares)	(4,431)
Equity-based compensation				421			421
Unrealized loss attributable to change in market value of available for sale investments						58	58
Net loss					(4,647)		(4,647)
Balance at Mar. 31, 2023	$ 6	$ 15	$ (100)	$ 84,116	$ (67,420)	$ (299)	$ 16,318
Balance (in Shares) at Mar. 31, 2023	6,163,050	14,871,085

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (4,647)	$ (3,510)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	238	188
Interest earned on marketable securities	72	54
Equity-based compensation	421	491
Changes in operating assets and liabilities:
Accounts and grants receivable	122	(41)
Prepaid expenses and other current assets	(694)	(908)
Other assets	(2)	(57)
Accounts payable	(1,294)	(7)
Deferred revenue	50	306
Accrued expenses	(38)	(604)
ROU asset and lease liability	(76)	(64)
Net cash used in operating activities	(5,848)	(4,152)
Cash flows from investing activities
Proceeds from the sale of Marketable securities	461	885
Acquisition of property and equipment	(42)	(47)
Acquisition of intangible assets	(73)	(71)
Net cash provided by investing activities	346	767
Cash flows from financing activities
Payments for taxes on RSUs vested	(17)	(141)
Net cash used in financing activities	(17)	(141)
Change in cash and cash equivalents	(5,519)	(3,526)
Cash and cash equivalents at beginning of the period	10,503	25,658
Cash and cash equivalents at end of the period	4,984	22,132
Supplement Disclosure of Non-cash Investing and Financing Activities:
Vesting of RSUs into Class A Common Stock	$ (68)	$ (379)

Nature of Business, Basis of Pr

Nature of Business, Basis of Presentation, and Liquidity	3 Months Ended
	Mar. 31, 2023
Nature of Business, Basis of Presentation, and Liquidity [Abstract]
Nature of Business, Basis of Presentation, and Liquidity	1. Nature of Business, Basis of Presentation, and Liquidity Nature of business: Longeveron, LLC was formed as a Delaware limited liability company on October 9, 2014, and was authorized to transact business in Florida on December 15, 2014. On February 12, 2021, Longeveron, LLC converted its corporate form (the “Corporate Conversion”) from a Delaware limited liability company (Longeveron, LLC) to a Delaware corporation, Longeveron Inc. (the “Company,” “Longeveron” or “we,” “us,” or “our”). The Company is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida. The Company’s product candidates are currently in development. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from, among others, existing pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, partners and consultants. The accompanying interim condensed balance sheet as of March 31, 2023, and the condensed statements of operations, statement of comprehensive loss, stockholders’ equity, and cash flows for the three months ended March 31, 2023 and 2022, are unaudited. The unaudited condensed financial statements have been prepared according to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) have been omitted. In the opinion of management, the accompanying unaudited condensed financial statements for the periods presented reflect all adjustments which are normal and recurring, and necessary to fairly state the financial position, results of operations, and cash flows of the Company. Liquidity: Since inception, the Company has primarily been engaged in organizational activities, including raising capital, and research and development activities. The Company does not yet have a product that has been approved by the U.S. Food and Drug Administration (“FDA”), and has only generated revenues from grants, clinical trials and contract manufacturing. The Company has not yet achieved profitable operations or generated positive cash flows from operations. The Company intends to continue its efforts to raise additional equity financing, develop its intellectual property, and secure regulatory approvals to commercialize its products. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital, its research and commercialization efforts, regulatory approval, and, ultimately, the market acceptance of the Company’s approved products, if any. These condensed financial statements do not include adjustments that might result from the outcome of these uncertainties. The Company has incurred recurring losses from operations since its inception, including a net loss of $4.6 million and $3.5 million for the three months ended March 31, 2023 and 2022, respectively. In addition, as of March 31, 2023, the Company had an accumulated deficit of $67.4 million. The Company expects to continue to generate operating losses for the foreseeable future. As of March 31, 2023, the Company had cash, and cash equivalents of $5.0 million and marketable securities of $8.7 million. The Company has prepared a cash flow forecast which indicates that it does not have sufficient cash to meet its minimum expenditure commitments for one year from the date these condensed financial statements are available to be issued and therefore needs to raise additional funds to continue as a going concern. As a result, there is substantial doubt about the Company’s ability to continue as a going concern. To address the future funding requirements, management has undertaken the following initiatives: ● the Company may seek additional capital in the private and/or public equity markets, to continue its operations, respond to competitive pressures, develop new products and services, and to support new strategic partnerships. The Company is evaluating additional equity/debt financing opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that the Company can consummate such a transaction or consummate a transaction at favorable pricing; ● the Company will attempt to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners; ● the Company plans to pursue potential partnerships for pipeline programs, however, there can be no assurances that it can consummate such transactions; ● the Company will continue to support its Bahamas Registry to generate revenue; and ● since 2016 our clinical programs have received over $16.0 million in competitive extramural grant awards ($11.5 million which has been directly awarded to us and which are recognized as revenue when the performance obligations are met) from the National Institutes of Health (NIH), Alzheimer’s Association, and Maryland Stem Cell Research Fund (MSCRF), and the Company plans to submit additional contract and grant applications for further support of its programs with various funding agencies. The Company’s condensed financial statements do not include any adjustments to the assets’ carrying amount, to the expenses presented and to the reclassification of the condensed balance sheets items that could be necessary should the Company be unable to continue its operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of presentation: The condensed financial statements of the Company were prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”). Certain reclassifications have been made to prior year condensed financial statements to conform to classifications used in the current year. These reclassifications had no impact on net loss, shareholders’ equity or cash flows as previously reported. Use of estimates: The presentation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Accounting Standard Updates A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed standards would have on the Company’s condensed financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The adoption of the standard as of January 1, 2023 did not have a material impact on the Company’s condensed financial statements; however, the Company did record a net unrealized loss in the statement of comprehensive loss for the three month period ended March 31, 2023. Cash and cash equivalents: The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. Marketable securities: Marketable securities at March 31, 2023 and December 31, 2022 consisted of marketable fixed income securities, primarily corporate bonds, as well as U.S. Government and agency obligations which are categorized as available for sale securities and are thus marked to market and stated at fair value in accordance with ASC 820 Fair Value Measurement Accounts and grants receivable: Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of March 31, 2023, and December 31, 2022 are certain to be collected, and no amount has been recognized for doubtful accounts. In addition, for the Clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the Clinical trial revenue are recorded to deferred revenue. Accounts and grants receivable by source, as of (in thousands): March 31, December 31, National Institutes of Health – Grant $ 96 $ 218 Total $ 96 $ 218 Deferred offering costs: The Company recorded certain legal, professional and other third-party fees that were directly associated with in-process equity financings as deferred offering costs until the applicable equity financing was consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity as a reduction of proceeds generated as a result of the offering. Property and equipment: Property and equipment, including improvements that extend useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company’s clinical programs. Intangible assets: Intangible assets include payments on license agreements with the Company’s co-founder and chief scientific officer (“CSO”) and the University of Miami (“UM”) (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired. Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from 5-20 years. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company’s clinical programs. Impairment of Long-Lived Assets: The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting impairment loss is reflected on the condensed statements of operations. Upon evaluation, management determined that there was no impairment of long-lived assets during the three months ended March 31, 2023 and 2022. Deferred revenue: The unearned portion of advanced grant funds and prepayments for Clinical trial revenue, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the accompanying condensed balance sheets. For the three months ended March 31, 2023 and 2022, the Company recognized $0 and $19,000 of funds that were previously classified as deferred revenue ($0.1 million and $0 million, respectively for the three months ended March 31, 2023 and 2022, respectively). Due to the MSCRF – Technology Development Corporation (TEDCO) – grant Accute Respiratory Distress Syndrome (ARDS) program being discontinued, the $0.4 million recorded as deferred revenue will be reversed when the funds are returned to MSCRF – TEDCO. Revenue recognition: The Company recognizes revenue when performance obligations related to respective revenue streams are met. For Grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred or supplies, and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For Clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant receives the treatment. For Contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and/or statement of work has been satisfied. Payment terms may vary depending on specific contract terms. There are no significant judgments affecting the determination of the amount and timing of revenue recognition. Revenue by source (in thousands): Three months ended 2023 2022 NIH - grant $ 41 $ 41 Clinical trial revenue 238 310 MSCRF – TEDCO - grant - 19 Total $ 279 $ 370 The Company records cost of revenues based on expenses directly related to revenue. For Grants, the Company records allocated expenses for Research and development costs to a grant as a cost of revenues. For the Clinical trial revenue, directly related expenses for that program are expensed as incurred. These expenses are similar to those described under “Research and development expense” below. Research and development expense: Research and development costs are charged to expense when incurred in accordance with ASC 730 Research and Development Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts. Income taxes: Prior to its Corporate Conversion, the Company was treated as a partnership for U.S. federal and state income tax purposes. Consequently, the Company passed its earnings and losses through to its members based on the terms of the Company’s Operating Agreement. Accordingly, no provision for income taxes is recorded in the condensed financial statements for periods prior to the conversion. Following the Corporate Conversion, the Company’s tax provision consists of taxes currently payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company’s tax provision was $0 for the three months ended March 31, 2023 and 2022 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the offset created by the Company’s valuation allowance. The Company recognizes the tax benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination, or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of March 31, 2023 and December 31, 2022, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to a taxing authority. It is the Company’s policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable. Equity-based compensation: The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for stock-based awards based on estimated fair values on the date of grant. The fair value of the options is estimated at the date of the grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the options. Neither the Company’s stock options nor its restricted stock units (“RSUs”) trade on an active market. Volatility is a measure of the amount by which a financial variable, such as a stock price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Given the Company’s limited historical data, the Company utilizes the average historical volatility of similar publicly traded companies that are in the same industry. The risk-free interest rate is the average U.S. treasury rate (having a term that most closely approximates the expected life of the option) for the period in which the option was granted. The expected life is the period of time that the options granted are expected to remain outstanding. Options granted have a maximum term of ten years. The Company has insufficient historical data to utilize in determining its expected life assumptions and, therefore, uses the simplified method for determining expected life.

Marketable securities

Marketable securities	3 Months Ended
	Mar. 31, 2023
Marketable securities [Abstract]
Marketable securities	3. Marketable securities The following is summary of Marketable securities that the Company measures at fair value: Fair Value at March 31, 2023 Level 1 Level 2 Level 3 Total U.S. Treasury obligations $ 98,133 $ - $ - $ 98,133 U.S. government agencies - 1,064,992 - 1,064,992 Corporate and foreign bonds - 7,530,053 - 7,530,053 Money market funds (1) 1,190,450 - - 1,190,450 Accrued income 66,862 - - 66,862 Total Marketable securities $ 1,355,445 $ 8,595,045 $ - $ 9,950,490 (1) Money market funds are included in cash and cash equivalents in the condensed balance sheet. Fair Value at December 31, 2022 Level 1 Level 2 Level 3 Total U.S. Treasury obligations $ 96,981 $ - $ - $ 96,981 U.S. government agencies - 1,250,003 - 1,250,003 Corporate and foreign bonds - 7,807,655 - 7,807,655 Money market funds (1) 607,263 - - 607,263 Accrued income 64,815 - - 64,815 Total Marketable securities $ 769,059 $ 9,057,658 $ - $ 9,826,717 (2) Money market funds are included in cash and cash equivalents in the condensed balance sheet. As of March 31, 2023, and December 31, 2022, the Company reported accrued interest receivable related to Marketable securities of $66,862 and $64,815, respectively. These amounts are recorded in other assets on the condensed balance sheets and are not included in the carrying value of the Marketable securities.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and equipment, net	4. Property and equipment, net Major components of property and equipment are as follows (in thousands): Useful Lives March 31, December 31, Leasehold improvements 10 years $ 4,328 $ 4,328 Furniture/Lab equipment 7 years 2,303 2,264 Computer equipment 5 years 49 46 Software/Website 3 years 38 38 Total property and equipment 6,718 6,676 Less accumulated depreciation and amortization 3,908 3,727 Property and equipment, net $ 2,810 $ 2,949 Depreciation and amortization expense amounted to approximately $0.2 million and $0.1 million for the three-month periods ended March 31, 2023 and 2022.

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2023
Intangible assets, net [Abstract]
Intangible assets, net	5. Intangible assets, net Major components of intangible assets as of March 31, 2023, are as follows (in thousands): Useful Lives Cost Accumulated Total License agreements 20 years $ 2,044 $ (742 ) $ 1,302 Patent Costs 951 - 951 Trademark costs 172 - 172 Total $ 3,167 $ (742 ) $ 2,425 Major components of intangible assets as of December 31, 2022, are as follows: Useful Lives Cost Accumulated Total License agreements 20 years $ 2,043 $ (685 ) $ 1,358 Patent Costs 887 - 887 Trademark costs 164 - 164 Total $ 3,094 $ (685 ) $ 2,409 Amortization expense related to intangible assets amounted to approximately $0.1 million for each of the three-month periods ended March 31, 2023 and 2022. Future amortization expense for intangible assets as of March 31, 2023, is approximately as follows (in thousands): Year Ending December 31, Amount 2023 (remaining nine months) $ 168 2024 224 2025 224 2026 224 2027 224 Thereafter 238 Total $ 1,302

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	6. Leases The Company records a Right-of-use (ROU) asset and a lease liability related to its operating leases (there are no finance leases). The Company’s corporate office lease expires in March 2027. As of March 31, 2023, the ROU asset and lease liability were approximately $1.5 million and $2.5 million, respectively. As of December 31, 2022, the ROU asset and lease liability were approximately $1.5 million and $2.6 million, respectively. Future minimum payments under the operating leases as of March 31, 2023, are as follows (in thousands): Year Ending December 31, Amount 2023 (remaining nine months) $ 518 2024 702 2025 718 2026 735 2027 185 Total 2,858 Less: Interest 392 Present Value of Lease Liability $ 2,466 During each of the three months ended March 31, 2023 and 2022, the Company incurred approximately $0.3 million of total lease costs, that are included in the general and administrative expenses in the condensed statements of operations. On July 1, 2020, the Company entered into a sublease agreement for a portion of its leased space for a one-year period ending June 30, 2021, with optional one-year renewal periods, and $10,000 in monthly payments. The sublease was terminated in the second quarter of 2022. For the three months ended March 31, 2023, $0 was recognized as sublease income as compared to $30,000 for the same period in 2022. For the year ended December 31, 2022, $27,000 was recognized as sublease income, due to the Company receiving $17,000 of equipment and $10,000 of security deposit forfeited.

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2023
Stockholders’ Equity [Abstract]
Stockholders’ Equity	7. Stockholders’ Equity Class A Common Stock On January 3, 2023, a total of 20,161 RSUs granted in connection with the Company’s IPO vested, of which 18,005 were held by Company employees. The Company is required to make mandatory tax withholding for the payment and satisfaction of income tax, social security tax, payroll tax, or payment on account of other tax related to withholding obligations that arise by reason of vesting of an RSU. The taxable income is calculated by multiplying the number of vested RSUs for each individual by the closing share price as of the vesting date ($3.37 on January 3, 2023) and a tax liability is calculated based on each individual’s tax bracket. As a result, on January 3, 2023, the Company recorded a tax liability of $15,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $17,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 4,431 shares of Class A Common Stock owned by the employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. On November 16, 2022, the Company accounted for but had not issued 48,140 RSUs convertible to unregistered shares of Class A Common Stock, with an aggregate value of $207,000 as payment for accrued expenses under a consulting agreement with Dr. Hare. On October 3, 2022, a total of 20,157 RSUs granted in connection with the Company’s IPO vested, of which 18,001 were held by Company employees. Based on the closing price of $3.75 on October 3, 2022, the Company recorded a tax liability of $16,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $18,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 4,204 shares of Class A Common Stock owned by the Company’s employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. On July 1, 2022, a total of 20,158 RSUs granted in connection with the Company’s IPO vested, of which 18,002 were held by Company employees. Based on the closing price of $5.94 on July 1, 2022, the Company recorded a tax liability of $26,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $28,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 4,726 shares of Class A Common Stock owned by the Company’s employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. On June 22, 2022, a total of 27,854 RSUs were granted to the Company’s former Chief Executive Officer, Geoff Green, in exchange for $170,000 of compensation, as agreed upon in connection with his separation. On June 3, 2022, a total of 26,666 RSUs that previously had been granted to our Chief Financial Officer and General Counsel vested. RSUs are taxable upon vesting based on the market value on the date of vesting. Based on a closing price of $8.73 on June 3, 2022, the Company recorded a tax liability of $55,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $57,000 for employee and employer taxes resulting from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 6,254 shares of Class A Common Stock owned by the employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. On April 4, 2022, a total of 1,167 RSUs that previously had been granted to our Chief Medical Officer vested. Based on the closing price of $12.85 on April 3, 2022, the Company recorded a tax liability of $5,000 for the employee and a corresponding tax liability for the Company of $1,000. In total, the Company paid $6,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 357 shares of Class A Common Stock owned by the Chief Medical Officer upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. On April 1, 2022, a total of 31,016 RSUs granted in connection with the Company’s IPO vested, of which 26,360 were held by Company employees. Based on the closing price of $15.61 on April 1, 2022, the Company recorded a tax liability of $105,000 for the employees and a corresponding tax liability for the Company of $14,000. In total, the Company paid $119,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 6,222 shares of Class A Common Stock owned by the Company’s employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. On April 1, 2022, a total of 2,500 RSUs that were previously granted to a member of the Company’s Board of Directors vested. On February 12, 2022, a total of 8,750 RSUs that were previously granted to members of the Company’s Board of Directors upon the completion of the IPO vested. On January 3, 2022, a total of 35,246 RSUs granted in connection with the Company’s IPO vested, of which 29,614 were held by Company employees. Based on the closing price of $12.09 on January 3, 2022, the Company recorded a tax liability of $92,000 for the employees and a corresponding tax liability for the Company of $14,000. In total, the Company paid $106,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 10,627 shares of Class A Common Stock owned by the Company’s employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. Class B Common Stock In connection with the Corporate Conversion, 2,000,000 outstanding Series A and B units were converted into 15,702,834 shares of our unregistered Class B Common Stock. Holders of Class A Common Stock generally have rights identical to holders of Class B Common Stock, except that holders of Class A Common Stock are entitled to one vote per share and holders of Class B Common Stock are entitled to five (5) votes per share. The holders of Class B Common Stock may convert each share of Class B Common Stock into one share of Class A Common Stock at any time at the holder’s option. Class B Common Stock is not publicly tradable. During the three months ended March 31, 2023, shareholders exchanged 20,000 shares of Class B Common Stock for 20,000 shares of Class A Common Stock. During the year ended December 31, 2022, shareholders exchanged 811,749 shares of Class B Common Stock for 811,749 shares of Class A Common Stock. Warrants As part of the IPO, the underwriter received warrants to purchase 106,400 shares of Class A Common Stock. The warrants are exercisable at any time and from time to time, in whole or in part, during the four and a half-year period commencing August 12, 2021, at a price of $12.00 per share and the fair value of warrants was approximately $0.5 million. During 2021, the underwriters assigned 95,760 of the warrants to its employees. As of December 31, 2021, 51,061 warrants have been exercised for Class A Common Stock shares at an exercise price of $12.00 for $612,732. As part of the 2021 PIPE Offering, the Company issued 1,169,288 warrants to investors to purchase up to a number of shares of Class A Common Stock equal to the number of shares of Class A Common Stock purchased by such investor in the offering, at an exercise price of $17.50 per share. The purchaser warrants are immediately exercisable, expire five years from the date of issuance and have certain downward pricing adjustment mechanisms, subject to a floor, as set forth in greater detail in the purchase warrants. In addition, the Company granted the underwriters warrants, under similar terms, to purchase 46,722 shares of Class A Common Stock, at an exercise price of $17.50 per share.

Equity Incentive Plan

Equity Incentive Plan	3 Months Ended
	Mar. 31, 2023
Equity Incentive Plan [Abstract]
Equity Incentive Plan	8. Equity Incentive Plan As part of the Company’s IPO, the Company adopted and approved the 2021 Incentive Award Plan (“2021 Incentive Plan”). Under the 2021 Incentive Plan, the Company may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent for which the Company competes. On March 1, 2023, the company granted Mr. Hashad a signing bonus of 50,000 Restricted Stock Units, which shall vest in quarterly installments on each of April 1, 2023, July 1, 2023, September 1, 2023, and December 31, 2023. Mr. Hashad will also be eligible to receive annual long-term equity incentive awards through 2026 consisting of 50,000 shares of time-based vesting stock options and up to 125,000 of performance share units, in accordance with the terms of the Longeveron 2021 Incentive Award Plan. On November 16, 2022, the Company accounted for but had not issued 48,140 RSUs convertible to unregistered shares of Class A Common Stock, with an aggregate value of $207,000 as payment for accrued expenses under a consulting agreement with Dr. Hare. On September 6, 2022, the Company granted Mr. Bailey received an equity incentive award of 20,000 RSUs. The RSUs will vest 25% upon the first-year anniversary of his first day of employment with Longeveron, with 25% vesting thereafter on the second, third and fourth anniversaries of his employment. In each case, the vesting of the equity awards will be subject to Mr. Bailey’s continued service through the applicable vesting dates. RSUs shall be expensed on a quarterly basis at the rate of $5,838 for the quarterly vesting amount of 1,250 RSUs, with a price per share of $4.67 (the closing price of the Company’s stock on September 6, 2022). On June 22, 2022, the Company granted $170,000 of separation compensation to Mr. Green (Mr. Green resigned as CEO effective June 1, 2022), which were converted into 27,854 RSUs. The RSU were issued based on the three-day average of the fair market value prior to the time of grant, June 22, 2022, of $6.10. On June 3, 2022, the Company granted a bonus to Mr. Clavijo and Mr. Lehr in the form of RSUs. Mr. Clavijo and Mr. Lehr were granted 40,000 RSUs each that vested one-third at the grant date, with the remaining two thirds vesting on each anniversary of the grant date. The RSU were issued based on a fair market value at the time of grant, June 3, 2022, of $8.73. On April 4, 2022, the Company appointed K. Chris Min, M.D., Ph.D. as its Chief Medical Officer. Dr. Min’s employment agreement provides annual base salary of $350,000, and he will be eligible to receive a performance bonus equal to 30% of his base salary, prorated for his first year of employment. Dr. Min received a $60,000 signing bonus, with 50% of this amount paid in RSUs and 50% in stock options. Dr. Min also received two equity incentive awards: 150,000 RSUs and a stock option award exercisable for 50,000 shares. Each award will vest 25% upon the first-year anniversary of his first day of employment with Longeveron, with 25% vesting thereafter on the second, third and fourth anniversaries of his employment. In each case, the vesting of the equity awards will be subject to Dr. Min’s continued service through the applicable vesting dates. RSUs shall be expensed on a quarterly basis at the rate of $0.1 million for the quarterly vesting amount of 9,375 RSUs, with a price per share of $12.85 (the closing price of the Company’s stock on April 4, 2022). Stock options shall be expensed based upon a Black-Scholes calculation, the price per share to be expensed was $11.34 and a total cost of $0.6 million would be expensed ratably over 48 months. As of March 31, 2023, and December 31, 2022, the Company had 356,297 and 329,746, respectively RSUs outstanding (unvested). RSU activity for the three months ended March 31, 2023, was as follows: Number of Outstanding (unvested) at December 31, 2022 329,746 RSU granted 50,000 RSUs vested (23,149 ) RSU expired/forfeited - Outstanding (unvested) at March 31, 2023 356,597 Stock Options Stock options may be granted under the 2021 Incentive Plan. The exercise price of options is equal to the fair market value of the Company’s Class A Common Stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. The 2021 Incentive Plan provides for equity grants to be granted up to 5% of the outstanding common stock shares. The fair value of the options issued are estimated using the Black-Scholes option-pricing model and have the following assumptions: a dividend yield of 0%; an expected life of 10 years; volatility of 95%; and risk-free interest rate based on the grant date ranging from of 1.23% to 3.68%. Each option grant made during 2023 and 2022, will be expensed ratably over the option vesting periods, which approximates the service period. As of March 31, 2023 and December 31, 2022, the Company has recorded issued and outstanding options to purchase a total of 470,191 shares of Class A Common Stock pursuant to the 2021 Incentive Plan, at a weighted average exercise price of $7.07 per share. For the three months ended March 31, 2023: Number of Stock options vested (based on ratable vesting) 194,120 Stock options unvested 276,071 Total stock options outstanding at March 31, 2023 470,191 For the year ended December 31, 2022: Number of Stock options vested (based on ratable vesting) 151,258 Stock options unvested 318,933 Total stock options outstanding at December 31, 2022 470,191 Stock Option activity for the three months ended March 31, 2023, was as follows: Number of Weighted Outstanding at December 31, 2022 470,191 $ 7.07 Options granted - - Options exercised - - Options expired/forfeited - - Outstanding at March 31, 2023 470,191 $ 7.07 On December 21, 2022, the Company granted an award of 5,000 Class A Common Stock options to each of its directors (a total of 45,000). The stock option award has a four-year vesting period, vesting 25% per year, and has an exercise price of $3.00. Based upon a Black-Scholes calculation, the price per share to be expensed was $2.67 and a total cost of $135,000 that would be expensed ratably over 48 months. On November 16, 2022, the Company granted an award of 22,843 Class A Common Stock options to Mr. Lehr. The stock option award has a four-year vesting period, vesting 25% per year, and has an exercise price of $4.30. Based upon a Black-Scholes calculation, the price per share to be expensed was $2.94 and a total cost of less than $0.1 million would be expensed ratably over 48 months. On September 6, 2022, the Company granted an award of 10,000 Class A Common Stock options to an employee. The stock option award has a four-year vesting period, vesting 25% per year, and has an exercise price of $4.67. Based upon a Black-Scholes calculation, the price per share to be expensed was $4.15 and a total cost of less than $0.1 million would be expensed ratably over 48 months. On June 3, 2022, the Company granted an award of 5,000 Class A Common Stock options to Mr. Lehr. The stock option award vested upon the grant date and has an exercise price of $8.73. Based upon a Black-Scholes calculation, the price per share to be expensed was $7.73 and a total cost of less than $0.1 million was expensed on the grant date. On March 14, 2022, the Company granted an award of 22,000 Class A Common Stock options to employees. The stock option award has a four-year vesting period, vesting 25% per year, and has an exercise price of $5.94. Based upon a Black-Scholes calculation, the price per share to be expensed was $5.23 and a total cost of less than $0.1 million would be expensed ratably over 48 months. On January 6, 2022, the Company granted awards of 84,825 Class A Common Stock options to employees. The stock option awards have four-year vesting periods, vesting 25% per year, and have an exercise price of $10.00. Based upon a Black-Scholes calculation, the price per share to be expensed was $8.78 and a total cost of $0.7 million would be expensed ratably over 48 months. For the three months ended March 31, 2023 and 2022, the equity-based compensation expense amounted to approximately $0.4 million and $0.5 million, respectively, which is included in the research and development and general and administrative expenses in the condensed statements of operations for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the remaining unrecognized equity-based compensation (which includes RSUs and stock options) of approximately $3.2 million will be recognized over approximately 3.9 years.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Master Services Agreements: As of March 31, 2023, the Company had three active master services agreements with third parties to conduct its clinical trials and manage clinical research programs and clinical development services. The Company expects these agreements or amended current agreements to have total expenditures of approximately $3.5 million over the next two years. As of December 31, 2022, the Company had two active master services agreements with third parties to conduct its clinical trials and manage clinical research programs and clinical development services on behalf of the Company. The Company expects these agreements or amended current agreements to have total expenditures of approximately $2.9 million over the next two years. On March 10, 2022, the Company entered into a clinical studies agreement with a third party in conjunction with an upcoming clinical trial in Japan. The agreement provides for payments totaling $1.0 million over the course of two years. Consulting Services Agreement: On November 20, 2014, the Company entered into a ten-year consulting services agreement with Dr. Joshua Hare, its CSO. Under the agreement, the Company has agreed to pay the CSO $265,000 annually. The compensation payments are for scientific knowledge, medical research, technical knowledge, skills, and abilities to be provided by the CSO to further develop the intellectual property rights assigned by the CSO to the Company. This agreement requires the CSO to also assign to the Company the exclusive right, title, and interest in any work product developed from his efforts during the term of this agreement. On November 16, 2022, the Company accounted for but had not issued 48,140 RSUs convertible to unregistered shares of Class A Common Stock, with an aggregate value of $0.2 million as payment for accrued expenses under the consulting agreement with the CSO. As of March 31, 2023 and December 31, 2022, the Company had an accrued balance due to the CSO of less than $0.1 million. Technology Services Agreement: On March 27, 2015, the Company entered into a technology services agreement with Optimal Networks, Inc. (a related company owned by a Dr. Joshua Hare’s brother-in-law) for use of information technology services. The Company agreed to issue the related party equity incentive units in the amount equal to 50% of the charges for invoiced services, with such equity to be issued annually on or about the anniversary date of the agreement. During 2017, the Company issued 1,901 Series C Units, and on November 22, 2019, and January 29, 2021, the Company issued 820 and 410 Series C Units, respectively, as payment for an aggregate of $0.2 million of accrued technology services. The Series C units were converted to 16,755 Class A common stock shares. As of March 31, 2023 and December 31, 2022, the Company owed less than $0.1 million, pursuant to this agreement, which is included in accounts payable in the March 31, 2023 and December 31, 2022 condensed balance sheets. Exclusive Licensing Agreements: UM Agreement On November 20, 2014, the Company entered into an Exclusive License Agreement with UM for the use of certain Aging-related frailty-related MSC technology rights developed by our Chief Science Officer at UM. The UM License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how specifically related to the development of the culture-expanded MSCs for aging-related frailty used at the IMSCs, all SOPs used to create the IMSCs, and all data supporting isolation, culture, expansion, processing, cryopreservation and management of the IMSCs. The Company is required to pay UM (i) a license issue fee of $5,000, (ii) a running royalty in an amount equal to three percent of annual net sales on products or services developed from the technology, payable on a country-by-country basis beginning on the date of first commercial sale through termination of the UM License Agreement, and which may be reduced to the extent we are required to pay royalties to a third party for the same product or process, (iii) escalating annual cash payments of up to fifty thousand dollars, subject to offset. The agreement extends for up to 20 years from the last date a product or process is commercialized from the technology and was amended in 2017 to modify certain milestone completion dates as detailed below In 2021 the license fee was increased by an additional $100,000, to defray patent costs. In addition, the Company issued 110,387 unregistered shares of Class A Common Stock to UM. The milestone payment amendments shifted the triggering payments to three payments of $500,000, to be paid within six months of: (a) the completion of the first Phase 3 clinical trial of the products (based upon the final data unblinding); (b) the receipt by the Company of approval for the first new drug application (“NDA”), biologics application (“BLA”), or other marketing or licensing application for the product; and (c) the first sale following product approval. “Approval” refers to Product approval, licensure, or other marketing authorization by the U.S. Food and Drug Administration, or any successor agency. The amendments also provided for the Company’s license of additional technology, to the extent not previously included in the UM License and granted the Company an exclusive option to obtain an exclusive license for (a) the HLHS IND with ckit+ cells; and (b) UMP-438 titled “Method of Determining Responsiveness to Cell Therapy in Dilated Cardiomyopathy.” The Company has the right to terminate the UM License upon 60 days’ prior written notice, and either party has the right to terminate upon a breach of the UM License. To date, the Company has made payments totaling $140,000 to UM, and as of March 31, 2023 and December 31, 2022, we had accrued $92,000 and $50,000 in milestone fees payable to UM, respectively and $100,000 for patent related reimbursements based on the estimated progress to date. CD271 On December 22, 2016, the Company entered into an exclusive license agreement with an affiliated entity of Dr. Joshua Hare, JMH MD Holdings, LLC (“JMHMD”), for the use of CD271 cellular therapy technology. The Company recorded the value of the cash consideration and membership units issued to obtain this license agreement as an intangible asset. The Company is required to pay as royalty, 1% of the annual net sales of the licensed product(s) used, leased, or sold by or for licensee or its sub-licensees. If the Company sublicenses the technology, it is also required to pay an amount equal to 10% of the net sales of the sub-licensees. In addition, on December 23, 2016, as required by the license agreement, the Company paid an initial fee of $250,000 to JMHMD, and issued to it 10,000 Series C Units, valued at $250,000. The $0.5 million of value provided to JMHMD for the license agreement, along with professional fees of approximately $27,000, were recorded as an intangible asset that is amortized over the life of the license agreement which was defined as 20 years. Further, expenses related to the furtherance of the CD271+ technology is being capitalized and amortized as incurred over 20 years. There were no license fees due for March 31, 2023 and December 31, 2022 pertaining to this agreement. Other Royalty Under the grant award agreement with the Alzheimer’s Association, the Company may be required to make revenue sharing or distribution of revenue payments for products or inventions generated or resulting from this clinical trial program. The potential payments, although not currently defined, could result in a maximum payment of five times (5x) the award amount. Contingencies – Legal On September 13, 2021, the Company and certain of our directors and officers were named as defendants in a securities lawsuit filed in the U.S. District Court for the Southern District of Florida and brought on behalf of a purported class. The suit alleges there were materially false and misleading statements made (or omissions of required information) in the Company’s initial public offering materials and in other disclosures during the period from our initial public offering on February 12, 2021, through August 12, 2021, in violation of the federal securities laws. The action seeks damages on behalf of a proposed class of purchasers of our Common Stock during said period. On July 12, 2022, all parties preliminarily agreed to settle the action for approximately $1.4 million, which amount was accrued as of March 31, 2023, and included in accrued expenses on the March 31, 2023 condensed balance sheet. The parties are in the process of documenting the settlement and full release, which will be subject to Court approval. Legal expenses incurred in ordinary business activities are reported within general and administrative expenses.

Employee Benefits Plan

Employee Benefits Plan	3 Months Ended
	Mar. 31, 2023
Employee Benefits Plan [Abstract]
Employee Benefits Plan	10. Employee Benefits Plan The Company sponsors a defined contribution employee benefit plan (the “Plan”) under the provisions of Section 401(k) of the Internal Revenue Code. The Plan covers substantially all full-time employees of the Company who have completed one year of service. Contributions to the Plan by the Company are at the discretion of the Board of Directors. The Company contributed approximately $38,000 and $32,000 to the Plan during the three months ended March 31, 2023 and 2022, respectively.

Loss Per Share

Loss Per Share	3 Months Ended
	Mar. 31, 2023
Loss Per Share [Abstract]
Loss Per Share	11. Loss Per Share Basic and diluted net loss per share have been computed using the weighted-average number of shares of common stock outstanding during the period. We have outstanding stock-based awards that are not used in the calculation of diluted net loss per share because to do so would be anti-dilutive. The following instruments (in thousands) were excluded from the calculation of diluted net loss per share because their effects would be antidilutive: Three months ended 2023 2022 RSUs 356 306 Stock options 470 304 Warrants 1,271 1,271 Total 2,097 1,881

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events On April 3, 2023, a total of 10,648 RSUs granted in connection with the Company’s IPO vested, of which 9,570 were held by Company employees. Based on the closing price of $2.61 on April 3, 2023, the Company recorded a tax liability of $7,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $9,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 2,514 shares of Class A Common Stock owned by the Company’s employees upon vesting. The shares withheld are available for reissuance pursuant to the 2021 Incentive Plan. On April 18, 2023, the Company finalized the Separation Agreement dated March 31, 2023, for Dr. Min (Company’s Chief Medical Officer). In part for his agreement to a general release the Company agreed to pay Dr. Min: $112,000 as severance compensation and the immediate acceleration and vesting of 40,000 RSUs that were previously granted. On April 19, 2023, the Company finalized the Separation Agreement effective June 9, 2023, for Mr. Clavijo (Company’s Chief Financial Officer). In part for his agreement to a general release the Company agreed to pay Mr. Clavijo $275,000 as severance compensation, three months of payment for COBRA insurance coverage and the immediate acceleration and vesting of 6,690 RSUs that were previously granted.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of presentation	Basis of presentation: The condensed financial statements of the Company were prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”). Certain reclassifications have been made to prior year condensed financial statements to conform to classifications used in the current year. These reclassifications had no impact on net loss, shareholders’ equity or cash flows as previously reported.
Use of estimates	Use of estimates: The presentation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Accounting Standard Updates	Accounting Standard Updates A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed standards would have on the Company’s condensed financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The adoption of the standard as of January 1, 2023 did not have a material impact on the Company’s condensed financial statements; however, the Company did record a net unrealized loss in the statement of comprehensive loss for the three month period ended March 31, 2023.
Cash and cash equivalents	Cash and cash equivalents: The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.
Marketable Securities	Marketable securities: Marketable securities at March 31, 2023 and December 31, 2022 consisted of marketable fixed income securities, primarily corporate bonds, as well as U.S. Government and agency obligations which are categorized as available for sale securities and are thus marked to market and stated at fair value in accordance with ASC 820 Fair Value Measurement
Accounts and grants receivable	Accounts and grants receivable: Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of March 31, 2023, and December 31, 2022 are certain to be collected, and no amount has been recognized for doubtful accounts. In addition, for the Clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the Clinical trial revenue are recorded to deferred revenue. Accounts and grants receivable by source, as of (in thousands): March 31, December 31, National Institutes of Health – Grant $ 96 $ 218 Total $ 96 $ 218
Deferred offering costs	Deferred offering costs: The Company recorded certain legal, professional and other third-party fees that were directly associated with in-process equity financings as deferred offering costs until the applicable equity financing was consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity as a reduction of proceeds generated as a result of the offering.
Property and equipment	Property and equipment: Property and equipment, including improvements that extend useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company’s clinical programs.
Intangible assets	Intangible assets: Intangible assets include payments on license agreements with the Company’s co-founder and chief scientific officer (“CSO”) and the University of Miami (“UM”) (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired. Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from 5-20 years. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the condensed statements of operations as the assets are primarily related to the Company’s clinical programs.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets: The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting impairment loss is reflected on the condensed statements of operations. Upon evaluation, management determined that there was no impairment of long-lived assets during the three months ended March 31, 2023 and 2022.
Deferred revenue	Deferred revenue: The unearned portion of advanced grant funds and prepayments for Clinical trial revenue, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the accompanying condensed balance sheets. For the three months ended March 31, 2023 and 2022, the Company recognized $0 and $19,000 of funds that were previously classified as deferred revenue ($0.1 million and $0 million, respectively for the three months ended March 31, 2023 and 2022, respectively). Due to the MSCRF – Technology Development Corporation (TEDCO) – grant Accute Respiratory Distress Syndrome (ARDS) program being discontinued, the $0.4 million recorded as deferred revenue will be reversed when the funds are returned to MSCRF – TEDCO.
Revenue recognition	Revenue recognition: The Company recognizes revenue when performance obligations related to respective revenue streams are met. For Grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred or supplies, and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For Clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant receives the treatment. For Contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and/or statement of work has been satisfied. Payment terms may vary depending on specific contract terms. There are no significant judgments affecting the determination of the amount and timing of revenue recognition. Revenue by source (in thousands): Three months ended 2023 2022 NIH - grant $ 41 $ 41 Clinical trial revenue 238 310 MSCRF – TEDCO - grant - 19 Total $ 279 $ 370 The Company records cost of revenues based on expenses directly related to revenue. For Grants, the Company records allocated expenses for Research and development costs to a grant as a cost of revenues. For the Clinical trial revenue, directly related expenses for that program are expensed as incurred. These expenses are similar to those described under “Research and development expense” below.
Research and development expense	Research and development expense: Research and development costs are charged to expense when incurred in accordance with ASC 730 Research and Development
Concentrations of credit risk	Concentrations of credit risk: Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts.
Income taxes	Income taxes: Prior to its Corporate Conversion, the Company was treated as a partnership for U.S. federal and state income tax purposes. Consequently, the Company passed its earnings and losses through to its members based on the terms of the Company’s Operating Agreement. Accordingly, no provision for income taxes is recorded in the condensed financial statements for periods prior to the conversion. Following the Corporate Conversion, the Company’s tax provision consists of taxes currently payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company’s tax provision was $0 for the three months ended March 31, 2023 and 2022 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the offset created by the Company’s valuation allowance. The Company recognizes the tax benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination, or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of March 31, 2023 and December 31, 2022, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to a taxing authority. It is the Company’s policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable.
Equity-based compensation	Equity-based compensation: The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for stock-based awards based on estimated fair values on the date of grant. The fair value of the options is estimated at the date of the grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the options. Neither the Company’s stock options nor its restricted stock units (“RSUs”) trade on an active market. Volatility is a measure of the amount by which a financial variable, such as a stock price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Given the Company’s limited historical data, the Company utilizes the average historical volatility of similar publicly traded companies that are in the same industry. The risk-free interest rate is the average U.S. treasury rate (having a term that most closely approximates the expected life of the option) for the period in which the option was granted. The expected life is the period of time that the options granted are expected to remain outstanding. Options granted have a maximum term of ten years. The Company has insufficient historical data to utilize in determining its expected life assumptions and, therefore, uses the simplified method for determining expected life.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Schedule of accounts and grants receivable	March 31, December 31, National Institutes of Health – Grant $ 96 $ 218 Total $ 96 $ 218
Schedule of revenue	Three months ended 2023 2022 NIH - grant $ 41 $ 41 Clinical trial revenue 238 310 MSCRF – TEDCO - grant - 19 Total $ 279 $ 370

Marketable securities (Tables)

Marketable securities (Tables)	3 Months Ended
	Mar. 31, 2023
Marketable securities [Abstract]
Schedule of marketable securities	Fair Value at March 31, 2023 Level 1 Level 2 Level 3 Total U.S. Treasury obligations $ 98,133 $ - $ - $ 98,133 U.S. government agencies - 1,064,992 - 1,064,992 Corporate and foreign bonds - 7,530,053 - 7,530,053 Money market funds (1) 1,190,450 - - 1,190,450 Accrued income 66,862 - - 66,862 Total Marketable securities $ 1,355,445 $ 8,595,045 $ - $ 9,950,490 (1) Money market funds are included in cash and cash equivalents in the condensed balance sheet. Fair Value at December 31, 2022 Level 1 Level 2 Level 3 Total U.S. Treasury obligations $ 96,981 $ - $ - $ 96,981 U.S. government agencies - 1,250,003 - 1,250,003 Corporate and foreign bonds - 7,807,655 - 7,807,655 Money market funds (1) 607,263 - - 607,263 Accrued income 64,815 - - 64,815 Total Marketable securities $ 769,059 $ 9,057,658 $ - $ 9,826,717 (2) Money market funds are included in cash and cash equivalents in the condensed balance sheet.

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of major components of property and equipment	Useful Lives March 31, December 31, Leasehold improvements 10 years $ 4,328 $ 4,328 Furniture/Lab equipment 7 years 2,303 2,264 Computer equipment 5 years 49 46 Software/Website 3 years 38 38 Total property and equipment 6,718 6,676 Less accumulated depreciation and amortization 3,908 3,727 Property and equipment, net $ 2,810 $ 2,949

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Intangible assets, net [Abstract]
Schedule of major components of intangible assets	Useful Lives Cost Accumulated Total License agreements 20 years $ 2,044 $ (742 ) $ 1,302 Patent Costs 951 - 951 Trademark costs 172 - 172 Total $ 3,167 $ (742 ) $ 2,425 Useful Lives Cost Accumulated Total License agreements 20 years $ 2,043 $ (685 ) $ 1,358 Patent Costs 887 - 887 Trademark costs 164 - 164 Total $ 3,094 $ (685 ) $ 2,409
Schedule of future amortization expense for intangible assets	Year Ending December 31, Amount 2023 (remaining nine months) $ 168 2024 224 2025 224 2026 224 2027 224 Thereafter 238 Total $ 1,302

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule of future minimum payments under the operating leases	Year Ending December 31, Amount 2023 (remaining nine months) $ 518 2024 702 2025 718 2026 735 2027 185 Total 2,858 Less: Interest 392 Present Value of Lease Liability $ 2,466

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	3 Months Ended
	Mar. 31, 2023
Equity Incentive Plan [Abstract]
Schedule of RSU activity	Number of Outstanding (unvested) at December 31, 2022 329,746 RSU granted 50,000 RSUs vested (23,149 ) RSU expired/forfeited - Outstanding (unvested) at March 31, 2023 356,597
Schedule of issued and outstanding options	Number of Stock options vested (based on ratable vesting) 194,120 Stock options unvested 276,071 Total stock options outstanding at March 31, 2023 470,191 Number of Stock options vested (based on ratable vesting) 151,258 Stock options unvested 318,933 Total stock options outstanding at December 31, 2022 470,191
Schedule of stock option activity	Number of Weighted Outstanding at December 31, 2022 470,191 $ 7.07 Options granted - - Options exercised - - Options expired/forfeited - - Outstanding at March 31, 2023 470,191 $ 7.07

Loss Per Share (Tables)

Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Loss Per Share [Abstract]
Schedule of calculation of diluted net loss per share	Three months ended 2023 2022 RSUs 356 306 Stock options 470 304 Warrants 1,271 1,271 Total 2,097 1,881

Nature of Business, Basis of _2

Nature of Business, Basis of Presentation, and Liquidity (Details) - USD ($) $ / shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Nature of Business, Basis of Presentation, and Liquidity (Details) [Line Items]
Recurring loss	$ 4.6	$ 3.5
Accumulated deficit	67.4
Cash and cash equivalents	5
Marketable securities	$ 8.7
Class A Common Stock [Member] | Over-Allotment Option [Member]
Nature of Business, Basis of Presentation, and Liquidity (Details) [Line Items]
Sale of stock price, per share (in Dollars per share)	$ 16
Aggregate gross proceeds	$ 11.5

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Summary of Significant Accounting Policies (Details) [Line Items]
Net unrealized losses	$ 300	$ 0
Deferred revenue	100	0
Tax provision	$ 0	0
Options granted maximum term	10 years
Minimum [Member] | Intangible Assets [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
intangible assets estimated useful life	5 years
Maximum [Member] | Intangible Assets [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
intangible assets estimated useful life	20 years
Clinical trial revenue [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Revenue	$ 0	$ 19,000
ARDS [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Deferred revenue	$ 400

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of accounts and grants receivable - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts and grants receivable	$ 96	$ 218
National Institutes of Health – Grant [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts and grants receivable	$ 96	$ 218

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of revenue - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 279	$ 370
NIH - grant [Member]
Disaggregation of Revenue [Line Items]
Revenue	41	41
Clinical trial revenue [Member]
Disaggregation of Revenue [Line Items]
Revenue	238	310
MSCRF – TEDCO - grant [Member]
Disaggregation of Revenue [Line Items]
Revenue		$ 19

Marketable securities (Details)

Marketable securities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Marketable securities [Abstract]
Accrued interest	$ 66,862	$ 64,815

Marketable securities (Detail_2

Marketable securities (Details) - Schedule of marketable securities - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023		Dec. 31, 2022
Marketable securities (Details) - Schedule of marketable securities [Line Items]
U.S. Treasury obligations	$ 98,133		$ 96,981
U.S. government agencies	1,064,992		1,250,003
Corporate and foreign bonds	7,530,053		7,807,655
Money market funds	1,190,450	[1]	607,263	[2]
Accrued income	66,862		64,815
Total Marketable securities	9,950,490		9,826,717
Level 1 [Member]
Marketable securities (Details) - Schedule of marketable securities [Line Items]
U.S. Treasury obligations	98,133		96,981
U.S. government agencies
Corporate and foreign bonds
Money market funds	1,190,450	[1]	607,263	[2]
Accrued income	66,862		64,815
Total Marketable securities	1,355,445		769,059
Level 2 [Member]
Marketable securities (Details) - Schedule of marketable securities [Line Items]
U.S. Treasury obligations
U.S. government agencies	1,064,992		1,250,003
Corporate and foreign bonds	7,530,053		7,807,655
Money market funds
Accrued income
Total Marketable securities	8,595,045		9,057,658
Level 3 [Member]
Marketable securities (Details) - Schedule of marketable securities [Line Items]
U.S. Treasury obligations
U.S. government agencies
Corporate and foreign bonds
Money market funds		[1]
Accrued income
Total Marketable securities
[1]Money market funds are included in cash and cash equivalents in the condensed balance sheet.[2]Money market funds are included in cash and cash equivalents in the condensed balance sheet.

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 0.2	$ 0.1

Property and Equipment, Net (_2

Property and Equipment, Net (Details) - Schedule of major components of property and equipment - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 6,718	$ 6,676
Less accumulated depreciation and amortization	3,908	3,727
Property and equipment, net	$ 2,810	2,949
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful Lives	10 years
Total property and equipment	$ 4,328	4,328
Furniture/Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful Lives	7 years
Total property and equipment	$ 2,303	2,264
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful Lives	5 years
Total property and equipment	$ 49	46
Software/Website [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful Lives	3 years
Total property and equipment	$ 38	$ 38

Intangible Assets, Net (Details

Intangible Assets, Net (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Intangible assets, net [Abstract]
Amortization expense related to intangible assets	$ 0.1	$ 0.1

Intangible Assets, Net (Detai_2

Intangible Assets, Net (Details) - Schedule of major components of intangible assets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Intangible Assets, Net (Details) - Schedule of major components of intangible assets [Line Items]
Cost	$ 3,167	$ 3,094
Accumulated amortization	(742)	(685)
Intangible assets total	2,425	2,409
License agreements [Member]
Intangible Assets, Net (Details) - Schedule of major components of intangible assets [Line Items]
Cost	2,044	2,043
Accumulated amortization	(742)	(685)
Intangible assets total	$ 1,302	$ 1,358
License agreements [Member] | Minimum [Member]
Intangible Assets, Net (Details) - Schedule of major components of intangible assets [Line Items]
Useful lives	20 years	20 years
Trademark costs [Member]
Intangible Assets, Net (Details) - Schedule of major components of intangible assets [Line Items]
Cost	$ 172	$ 164
Intangible assets total	172	164
Patent Costs [Member]
Intangible Assets, Net (Details) - Schedule of major components of intangible assets [Line Items]
Cost	951	887
Intangible assets total	$ 951	$ 887

Intangible Assets, Net (Detai_3

Intangible Assets, Net (Details) - Schedule of future amortization expense for intangible assets $ in Thousands	Dec. 31, 2022 USD ($)
Schedule of future amortization expense [Abstract]
2023 (remaining nine months)	$ 168
2024	224
2025	224
2026	224
2027	224
Thereafter	238
Total	$ 1,302

Leases (Details)

Leases (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Jul. 01, 2020
Disclosure Text Block [Abstract]
Right of use asset	$ 1,500,000		$ 1,500,000
Lease liability	2,500,000		2,600,000
Lease costs	300,000	$ 300,000
Lease period				1 year
Monthly payments				$ 10,000
Sublease income	$ 0	$ 30,000	27,000
Receiving of equipment			17,000
Security deposit forfeited			$ 10,000

Leases (Details) - Schedule of

Leases (Details) - Schedule of future minimum payments under the operating leases $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Schedule of Future Minimum Payments Under the Operating Leases [Abstract]
2023 (remaining nine months)	$ 518
2024	702
2025	718
2026	735
2027	185
Total	2,858
Less: Interest	392
Present Value of Lease Liability	$ 2,466

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)													1 Months Ended			3 Months Ended	12 Months Ended
	Jan. 03, 2023	Oct. 03, 2022	Sep. 06, 2022	Jul. 01, 2022	Jun. 03, 2022	Apr. 04, 2022	Apr. 01, 2022	Mar. 14, 2022	Feb. 12, 2022	Jan. 06, 2022	Jan. 03, 2022	Aug. 12, 2021	Dec. 21, 2022	Nov. 16, 2022	Jun. 22, 2022	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Stockholders’ Equity (Details) [Line Items]
Granted shares	20,161	20,157	10,000	20,158	26,666	1,167	31,016	22,000	8,750	84,825	35,246			22,843	27,854
Vested shares	18,005	18,001		18,002			26,360				29,614
Share price (in Dollars per share)	$ 3.37
Tax liability (in Dollars)	$ 15,000
Employee and employer taxes paid (in Dollars)					$ 55,000											$ 17,000
Closing price per share (in Dollars per share)		$ 3.75		$ 5.94	$ 8.73		$ 15.61				$ 12.09
Directors vested description		the Company recorded a tax liability of $16,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $18,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 4,204 shares of Class A Common Stock owned by the Company’s employees upon vesting.		the Company recorded a tax liability of $26,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $28,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 4,726 shares of Class A Common Stock owned by the Company’s employees upon vesting.		Based on the closing price of $12.85 on April 3, 2022, the Company recorded a tax liability of $5,000 for the employee and a corresponding tax liability for the Company of $1,000. In total, the Company paid $6,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 357 shares of Class A Common Stock owned by the Chief Medical Officer upon vesting.	the Company recorded a tax liability of $105,000 for the employees and a corresponding tax liability for the Company of $14,000. In total, the Company paid $119,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 6,222 shares of Class A Common Stock owned by the Company’s employees upon vesting.				the Company recorded a tax liability of $92,000 for the employees and a corresponding tax liability for the Company of $14,000. In total, the Company paid $106,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 10,627 shares of Class A Common Stock owned by the Company’s employees upon vesting.
Compensation amount (in Dollars)															$ 170,000
Cash paid (in Dollars)					$ 57,000
Warrants exercise price per share (in Dollars per share)																$ 17.5
Fair value of warrants (in Dollars)												$ 500,000
underwriters warrants																		95,760
Warrants expire term																5 years
Tax liability [Member]
Stockholders’ Equity (Details) [Line Items]
Tax liability (in Dollars)	$ 2,000
IPO [Member]
Stockholders’ Equity (Details) [Line Items]
Public offering price per share (in Dollars per share)																$ 20,000
Gross proceeds (in Dollars)																$ 20,000
Class A Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Granted shares													5,000
Employee and employer taxes paid (in Dollars)					$ 2,000											$ 4,431
Common stock shares					6,254
Conversion of outstanding shares																16,755	16,755
Shares issued																110,387	811,749
Warrants exercise price per share (in Dollars per share)																$ 17.5
Warrants exercised																		51,061
Exercise price per share (in Dollars per share)																		$ 12
Exercise warrants amount (in Dollars)																		$ 612,732
Warrants issued to investors																1,169,288
Class A Common Stock [Member] | Warrants [Member]
Stockholders’ Equity (Details) [Line Items]
Shares issued																46,722
Warrants to purchase of common stock shares																106,400
Warrants exercise price per share (in Dollars per share)												$ 12
Series C Units [Member]
Stockholders’ Equity (Details) [Line Items]
Additional shares issued														48,140
Series C Units [Member] | Consulting Agreements [Member]
Stockholders’ Equity (Details) [Line Items]
Aggregate value (in Dollars)														$ 207,000
Class B Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Outstanding shares conversion																2,000,000
Conversion of outstanding shares																15,702,834
Shares issued																	811,749
Board of Directors [Member]
Stockholders’ Equity (Details) [Line Items]
Granted shares							2,500

Equity Incentive Plan (Details)

Equity Incentive Plan (Details) - USD ($)													1 Months Ended			3 Months Ended
	Mar. 01, 2023	Jan. 03, 2023	Oct. 03, 2022	Sep. 06, 2022	Jul. 01, 2022	Jun. 03, 2022	Apr. 04, 2022	Apr. 01, 2022	Mar. 14, 2022	Feb. 12, 2022	Jan. 06, 2022	Jan. 03, 2022	Dec. 21, 2022	Nov. 16, 2022	Jun. 22, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Equity Incentive Plan (Details) [Line Items]
RSUs convertible shares																470,191		470,191
Time-based vesting stock option shares	50,000
Performance share	125,000
Aggregate value (in Dollars)														$ 207,000
Granted awards		20,161	20,157	10,000	20,158	26,666	1,167	31,016	22,000	8,750	84,825	35,246		22,843	27,854
Vest first year anniversary percentage				25%
Vest third year anniversary percentage				25%
Vest second year anniversary percentage				25%
Vest fourth year anniversary percentage				25%
Employment agreement description							the Company appointed K. Chris Min, M.D., Ph.D. as its Chief Medical Officer. Dr. Min’s employment agreement provides annual base salary of $350,000, and he will be eligible to receive a performance bonus equal to 30% of his base salary, prorated for his first year of employment. Dr. Min received a $60,000 signing bonus, with 50% of this amount paid in RSUs and 50% in stock options. Dr. Min also received two equity incentive awards: 150,000 RSUs and a stock option award exercisable for 50,000 shares. Each award will vest 25% upon the first-year anniversary of his first day of employment with Longeveron, with 25% vesting thereafter on the second, third and fourth anniversaries of his employment. In each case, the vesting of the equity awards will be subject to Dr. Min’s continued service through the applicable vesting dates. RSUs shall be expensed on a quarterly basis at the rate of $0.1 million for the quarterly vesting amount of 9,375 RSUs, with a price per share of $12.85 (the closing price of the Company’s stock on April 4, 2022). Stock options shall be expensed based upon a Black-Scholes calculation, the price per share to be expensed was $11.34 and a total cost of $0.6 million would be expensed ratably over 48 months.
RSUs outstanding																356,297		329,746
Outstanding common stock shares																5%
Dividend yield																0%
Expected life																10 years
Volatility																95%
Directors total (in Dollars)													$ 45,000
Vesting period				25%					25%		25%		25%	25%
Exercise price (in Dollars per share)				$ 4.67					$ 5.94		$ 10		$ 3	$ 4.3
Calculation price (in Dollars per share)				$ 4.15					$ 5.23		$ 8.78		$ 2.67	$ 2.94
Total cost (in Dollars)				$ 100,000					$ 100,000		$ 700,000		$ 135,000	$ 100,000
Expensed ratably over				48 months					48 months		48 months		48 months	48 months
Equity based compensation expense (in Dollars)																$ 400,000	$ 500,000
Unrecognized equity based compensation (in Dollars)																$ 3,200,000
RSUs and stock options, term																3 years 10 months 24 days
Minimum [Member]
Equity Incentive Plan (Details) [Line Items]
Risk-free interest rate																1.23%
Maximum [Member]
Equity Incentive Plan (Details) [Line Items]
Risk-free interest rate																3.68%
Class A Common Stock
Equity Incentive Plan (Details) [Line Items]
RSUs convertible shares														48,140
Granted awards													5,000
Issued and outstanding options																470,191		470,191
Weighted average exercise price (in Dollars per share)																$ 7.07
Mr. Bailey [Member]
Equity Incentive Plan (Details) [Line Items]
RSUs convertible shares				1,250
Granted awards				20,000
Quarterly basis rate (in Dollars)				$ 5,838
Price per share (in Dollars per share)				$ 4.67
Mr. Green [Member]
Equity Incentive Plan (Details) [Line Items]
RSUs convertible shares															27,854
Compensation granted shares															170,000
Fair market value prior grant (in Dollars per share)															$ 6.1
Mr. Clavijo [Member]
Equity Incentive Plan (Details) [Line Items]
RSUs convertible shares						40,000
Fair market value prior grant (in Dollars per share)						$ 8.73
Mr. Lehr [Member] | Class A Common Stock
Equity Incentive Plan (Details) [Line Items]
Granted awards						5,000
Exercise price (in Dollars per share)						$ 8.73
Calculation price (in Dollars per share)						$ 7.73
Total cost (in Dollars)						$ 100,000
Restricted Stock Units (RSUs) [Member]
Equity Incentive Plan (Details) [Line Items]
RSUs convertible shares	50,000

Equity Incentive Plan (Detail_2

Equity Incentive Plan (Details) - Schedule of RSU activity	3 Months Ended
	Mar. 31, 2023 shares
Schedule of Rsu Activity [Abstract]
Outstanding (unvested) at December 31, 2022	329,746
RSU granted	50,000
RSUs vested	(23,149)
RSU expired/forfeited
Outstanding (unvested) at March 31, 2023	356,597

Equity Incentive Plan (Detail_3

Equity Incentive Plan (Details) - Schedule of issued and outstanding options - shares	Mar. 31, 2023	Dec. 31, 2022
Equity Incentive Plan (Details) - Schedule of issued and outstanding options [Line Items]
Total stock options granted	470,191	470,191
Stock options vested [Member]
Equity Incentive Plan (Details) - Schedule of issued and outstanding options [Line Items]
Total stock options granted	194,120	151,258
Stock options unvested [Member]
Equity Incentive Plan (Details) - Schedule of issued and outstanding options [Line Items]
Total stock options granted	276,071	318,933

Equity Incentive Plan (Detail_4

Equity Incentive Plan (Details) - Schedule of stock option activity - Stock Option Activity [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Equity Incentive Plan (Details) - Schedule of stock option activity [Line Items]
Number of Stock Options Outstanding beginning | shares	470,191
Weighted Average Exercise Price Outstanding beginning | $ / shares	$ 7.07
Number of Stock Options Options granted | shares
Weighted Average Exercise Price Options granted | $ / shares
Number of Stock Option Options exercised | shares
Weighted Average Exercise Price Options exercised | $ / shares
Number of Stock Option Options expired/forfeited | shares
Weighted Average Exercise Price Options expired/forfeited | $ / shares
Number of Stock Options Outstanding ending | shares	470,191
Weighted Average Exercise Price Outstanding ending | $ / shares	$ 7.07

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Nov. 16, 2022	Nov. 20, 2014	Mar. 31, 2023	Dec. 31, 2022	Jan. 29, 2021	Nov. 22, 2019	Dec. 31, 2017
Commitments and Contingencies (Details) [Line Items]
Agreements amount			$ 3,500,000
Payments term			2 years
Payments totaling			$ 140,000	$ 140,000
Issuance of additional unregistered shares (in Shares)	48,140
Accrued expenses	$ 200,000
Incentive units			50%
Aggregate of accrued technology services							$ 200,000
Owed amount			$ 100,000	100,000
License issue fees			$ 5,000
Agreement term			20 years
Additional cost			$ 100,000
Defray patent costs			500,000
Accrued amount			92,000	$ 50,000
Reimbursements based amount			$ 100,000
Agreement, description			The Company is required to pay as royalty, 1% of the annual net sales of the licensed product(s) used, leased, or sold by or for licensee or its sub-licensees. If the Company sublicenses the technology, it is also required to pay an amount equal to 10% of the net sales of the sub-licensees. In addition, on December 23, 2016, as required by the license agreement, the Company paid an initial fee of $250,000 to JMHMD, and issued to it 10,000 Series C Units, valued at $250,000. The $0.5 million of value provided to JMHMD for the license agreement, along with professional fees of approximately $27,000, were recorded as an intangible asset that is amortized over the life of the license agreement which was defined as 20 years. Further, expenses related to the furtherance of the CD271+ technology is being capitalized and amortized as incurred over 20 years. There were no license fees due for March 31, 2023 and December 31, 2022 pertaining to this agreement.
Master Services Agreements [Member]
Commitments and Contingencies (Details) [Line Items]
Expenditure amount			$ 2,900,000
Payments totaling			1,000,000
Consulting Services Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Company expense		$ 265,000
Accrued balance			$ 100,000
Series C Units [Member]
Commitments and Contingencies (Details) [Line Items]
Shares issued (in Shares)					410	820	1,901
Common Class A [Member]
Commitments and Contingencies (Details) [Line Items]
Converted shares (in Shares)			16,755	16,755
Unregistered share issued (in Shares)			110,387	811,749

Employee Benefits Plan (Details

Employee Benefits Plan (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Employee Benefits Plan [Abstract]
Company contributed	$ 38,000	$ 32,000

Loss Per Share (Details) - Sche

Loss Per Share (Details) - Schedule of calculation of diluted net loss per share - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,097	1,881
RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	356	306
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	470	304
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,271	1,271

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Apr. 19, 2023	Apr. 18, 2023	Apr. 03, 2023
Subsequent Events (Details) [Line Items]
Vested shares	6,690	40,000
Closing price per share			$ 2.61
Company paid employer taxes			$ 9,000
Severance compensation	$ 275,000	$ 112,000
Maximum [Member]
Subsequent Events (Details) [Line Items]
Tax liability			7,000
Minimum [Member]
Subsequent Events (Details) [Line Items]
Tax liability			$ 2,000
Class A Common Stock
Subsequent Events (Details) [Line Items]
Tax liability shares			2,514
Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Subsequent Events (Details) [Line Items]
Vested shares			10,648
Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Subsequent Events (Details) [Line Items]
Vested shares			9,570